News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
NxStage Medical, Inc. Cuts Expected IPO Price Range
October 26, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Oct 26 (Reuters) - Medical device company NxStage Medical Inc. cut the expected price for its initial public offering to between $11 and $12 a share from a previous range of $13 to $15, according to a regulatory filing on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Gene therapy
MeiraGTx, spying hope in a failed trial, buys back eye disease gene therapy from J&J
April 16, 2026
·
2 min read
·
Annalee Armstrong
Deals
Obesity’s explosive growth continues as Q1 deals exceed total 2025 value
April 16, 2026
·
2 min read
·
Tristan Manalac
Podcast
J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer
April 15, 2026
·
1 min read
·
Heather McKenzie
Mergers & acquisitions
Lilly wants to bridge cancer care gap with $300M ADC biotech buy
April 14, 2026
·
1 min read
·
Gabrielle Masson
